Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
First-in-human trial shows promise for hard-to-treat ventricular tachycardia heart rhythms
ROCHESTER, Minn. — A first-in-human multicenter trial involving Mayo Clinic used a new ablation technique for patients with ventricular tachycardia, an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide. The trial tested needle ablation using in-catheter, heated, saline-enhance d, radio frequency energy, also known as SERF, to substantially increase heat transfer, compared to conventional ablation methods. The new process produces deeper, controllable lesion scars at sites inside the heart muscle.… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - August 2, 2022 Category: Research Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Misdiagnosis in Patient With Dizziness, Leg Weakness
(MedPage Today) -- Typical parkinsonian tremor can simulate atrial flutter or ventricular tachycardia on ECG (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 31, 2022 Category: Cardiology Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
Gilbert Gottfried, iconic comedian, dies at 67 after long illness
Gottfried died at 2:35 p.m. ET on Tuesday from Recurrent Ventricular Tachycardia due to Myotonic Dystrophy type II. #gilbertgottfried (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2022 Category: Consumer Health News Source Type: news
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Transcutaneous Magnetic Stimulation Promising Against VT Storm Transcutaneous Magnetic Stimulation Promising Against VT Storm
New data suggest transcutaneous magnetic stimulation of the left stellate ganglion is a promising and noninvasive strategy to reduce episodes of ventricular tachycardia storm.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - February 22, 2022 Category: Emergency Medicine Tags: Cardiology News Source Type: news
Is Ventricular Tachycardia Serious?
Title: Is Ventricular Tachycardia Serious?Category: Diseases and ConditionsCreated: 1/20/2022 12:00:00 AMLast Editorial Review: 1/20/2022 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - January 20, 2022 Category: Cardiology Source Type: news
Effect of Anesthesia Depth on RFCA of Ventricular Tachycardia Effect of Anesthesia Depth on RFCA of Ventricular Tachycardia
This study compared the effects of different anesthesia depths on the inducibility of ventricular tachycardia during radiofrequency catheter ablation and on postoperative outcomes.BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2022 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news
How one health system is using radiation to treat heart patients who ’ve run out of options
Ventricular tachycardia (VT) is a common, potentially life-threatening heart arrhythmia that occurs in the organ ’s lower chambers in patients with heart disease or heart failure, which can lead to sudden cardiac death. While there are a variety of treatments, not all of them work for people suffering from the disorder. One of the most common treatments, a cardiac catheter ablation, can fail nearly half of the time in preventing further episodes of VT. Medication is another option, but sometimes… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 12, 2021 Category: Biotechnology Authors: Laura Newpoff Source Type: news
Apple study finds Watch can detect more types of irregular heartbeats
The most common arrhythmias detected were premature atrial contractions, premature ventricular contractions, atrial tachycardia and nonsustained ventricular tachycardia. (Source: mobihealthnews)
Source: mobihealthnews - September 29, 2021 Category: Information Technology Source Type: news
What Is the Best Treatment of Ventricular Tachycardia?
Title: What Is the Best Treatment of Ventricular Tachycardia?Category: Diseases and ConditionsCreated: 9/2/2021 12:00:00 AMLast Editorial Review: 9/2/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 2, 2021 Category: Cardiology Source Type: news
Cardiac Manifestations 6 Months After Resolution of COVID-19 Cardiac Manifestations 6 Months After Resolution of COVID-19
This case of a patient with exertional dyspnea and ventricular tachycardia months after COVID-19 recovery suggests possible long-term cardiac involvement after resolution of even a mild case of COVID.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 8, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news